Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $5.6 million.

  • Beam Therapeutics' Depreciation and Depletion rose 155.25% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 103.0%. This contributed to the annual value of $21.9 million for FY2024, which is 955.93% up from last year.
  • As of Q3 2025, Beam Therapeutics' Depreciation and Depletion stood at $5.6 million, which was up 155.25% from $5.5 million recorded in Q2 2025.
  • Beam Therapeutics' Depreciation and Depletion's 5-year high stood at $5.6 million during Q2 2024, with a 5-year trough of $1.4 million in Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Depreciation and Depletion value was $4.8 million (recorded in 2023), while the average stood at $4.2 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 13333.33% in 2022, then plummeted by 68.15% in 2025.
  • Over the past 5 years, Beam Therapeutics' Depreciation and Depletion (Quarter) stood at $2.6 million in 2021, then surged by 54.12% to $3.9 million in 2022, then surged by 35.95% to $5.4 million in 2023, then increased by 1.51% to $5.4 million in 2024, then grew by 2.15% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $5.5 million for Q2 2025, and $5.5 million during Q1 2025.